FDA gives nod to drug for kidney cancer

Temsirolimus (Torisel, Wyeth), the first mTOR (mammalian target of rapamycin) inhibitor, was recently approved for the treatment of advanced renal cell carcinoma (RCC). "Torisel provides a new option for physicians for the treatment of renal cell carcinoma," said Cindy O'Bryant, Pharm.D., BCOP, assistant professor at the University of Colorado Health Sciences Center School of Pharmacy, Denver.

"Torisel shows promise in treating RCC—a hard tumor to treat," added James Trovato, Pharm.D., MBA, BCOP, associate professor of pharmacy practice at the University of Maryland School of Pharmacy. "It will probably be used as a first-line agent for patients with poor prognostic factors such as advanced or metastatic disease."

View Full Article